Setmelanotide Dosage Chart - Peptide Dosages

Setmelanotide (10 mg) Dosage Protocol

A cyclic octapeptide MC4R agonist, FDA-approved as IMCIVREE — but only for rare genetic obesity, Bardet-Biedl syndrome and acquired hypothalamic obesity, not for general weight loss. It works where the defect sits upstream of an intact receptor. 3 mg daily is both maintenance and maximum.

A cyclic octapeptide that agonizes the melanocortin-4 receptor directly, bypassing a broken upstream link in the leptin-melanocortin pathway. More potent at MC4R than alpha-MSH itself — which is why it works when POMC, PCSK1 or LEPR is defective but the receptor is intact.

Label schedule: start 2 mg daily (genetic obesity, age 12+) or 0.5 mg daily (acquired hypothalamic obesity) for 2 weeks, then 3 mg once daily each morning. 3 mg is the maximum. The approved product is a ready-to-use 10 mg/mL solution — it is never reconstituted.

FDA-approved, with randomized phase 3 data — but only for POMC/PCSK1/LEPR deficiency, Bardet-Biedl syndrome and acquired hypothalamic obesity. It is not approved for common obesity, and MC4R-knockout animals do not respond at all.

Quickstart Highlights

Setmelanotide (development code RM-493, marketed as IMCIVREE) is a synthetic cyclic octapeptide and a potent, selective agonist at the melanocortin-4 receptor (MC4R) — the node in the brain’s leptin-melanocortin pathway that translates energy-store signals into hunger and satiety[1]. It is studied, and now approved, for reducing body weight and hyperphagia in people whose obesity is caused by a specific broken link upstream of that receptor. It is the melanocortin family’s serious clinical success story, and it sits alongside the more familiar research melanocortins — Melanotan II and PT-141 — which hit related receptors for entirely different reasons.

The framing here matters more than usual, in both directions. Setmelanotide is FDA-approved [5] — but only for rare genetic and acquired hypothalamic obesity, not for general weight loss, and the published evidence says plainly that it works best exactly where the defect sits upstream of an intact MC4R[4]. Research-grade setmelanotide is also not the approved product: IMCIVREE is a ready-to-use sterile solution dispensed on prescription with clinical monitoring. Nothing here is medical advice; this page documents the published dosing record and evidence for educational and research purposes only.

Mix & measure Setmelanotide · 10 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Supplies Needed

The standard items a documented injectable protocol relies on. At 5 mg/mL the label’s doses land between 10 and 60 units on a U-100 syringe — comfortable volumes with no measurement difficulty.

Protocol Overview

At 5 mg/mL a reconstituted 10 mg vial holds 2 mL: about 3.3 days at the 3 mg maintenance dose, or 20 days at the 0.5 mg acquired-hypothalamic-obesity starting dose. Setmelanotide is dosed in milligrams rather than micrograms, so a vial goes quickly at maintenance — this is one of the few compounds here where the vial, not the diluent window, is the binding constraint.

That also puts the real-world economics in view. Daily 3 mg dosing consumes roughly 90 mg per month, which is an order of magnitude more peptide than most protocols on this site. The approved product’s 10 mg/mL, 1 mL multiple-dose vial covers about three days at maintenance for the same reason[5].

Dosing Protocol

The approved label schedule, converted to U-100 units at the 5 mg/mL you get from a 10 mg research vial in 2 mL. These are the doses a regulator reviewed for specific diagnosed conditions under medical supervision — they are documented here, not recommended.

Start — genetic obesity, age 12+[5]

2 mg once daily × 2 weeks

40 units (0.40 mL)

Start — acquired hypothalamic obesity[5]

0.5 mg once daily × 2 weeks

10 units (0.10 mL)

Maintenance — all indications[5]

3 mg once daily

60 units (0.60 mL)

Maximum dose[5]

3 mg daily — do not exceed

Timing[5]

Beginning of the day, subcutaneous

—

Why Setmelanotide draws research interest

These are the directions researchers and the peptide community most often explore Setmelanotide for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Approved — but not for what people assume

Setmelanotide is a genuine FDA-approved drug, and that fact gets borrowed to imply it is a weight-loss peptide. It is not. It replaces a missing satiety signal in people with specific diagnosed defects; where the pathway is intact, there is no missing signal to replace.

The experiment that defines its limits

Patients with POMC defects upstream of MC4R lost significantly more weight than MC4R-deficient patients or obese controls, and MC4R-knockout mice did not respond at all. Rarely is a drug's boundary drawn so cleanly by its own data.

A 2x error waiting to happen

IMCIVREE is a ready-to-use 10 mg/mL solution. A research vial of 10 mg in 2 mL is 5 mg/mL — half as concentrated. Anyone copying a volume from the label instead of recomputing the milligrams delivers half the intended dose.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

Research vials only: 2.0 mL bacteriostatic water per 10 mg vial → 5 mg/mL (3 mg = 60 U-100 units). The approved product ships as a solution and is never reconstituted[5].

Label dosing: start 0.5–2 mg daily by indication, titrate to 3 mg daily. 3 mg is the maximum[5].

Subcutaneous, once daily, at the beginning of the day[5]. Abdomen, thigh or upper arm, rotating sites.

FDA-approved — for POMC/PCSK1/LEPR deficiency, Bardet-Biedl syndrome and acquired hypothalamic obesity only[5]. Not approved for common obesity.

Dosing & Reconstitution Guide

Setmelanotide is one of the few compounds on this site where a genuine, regulator-reviewed human dosing schedule exists — so we document that schedule rather than a community convention. The important structural fact is that the ceiling is low and flat: 3 mg once daily is both the maintenance dose and the maximum, and the titration exists to manage tolerability, not to chase a bigger effect[5].

Standard / Gradual Approach

The approved schedule differs by indication and by age, which is the detail most summaries drop. For POMC, PCSK1 or LEPR deficiency and Bardet-Biedl syndrome, adults and patients 12 and older start at 2 mg once daily for 2 weeks, then move to the 3 mg maintenance dose. For acquired hypothalamic obesity, the starting dose is much lower — 0.5 mg once daily for 2 weeks — before titrating toward 3 mg. Younger patients start lower still and use weight-based maintenance dosing[5]. Every dose is subcutaneous, once daily, at the beginning of the day.

A researcher working from a lyophilized vial should note the two ways this goes wrong. First, the approved product is a 10 mg/mL ready-to-use solution; if you reconstitute a 10 mg research vial in 2 mL you have 5 mg/mL — half that concentration — and a dose copied across as “0.3 mL” rather than recomputed in milligrams is a 2× error. Second, the label’s escalation is deliberately slow because of tolerability, not potency: going above 3 mg is not part of any approved protocol, and there is no published evidence that more produces more.

Reconstitution Steps

This section applies only to research-grade lyophilized material. The approved IMCIVREE product is supplied as a sterile solution in a multiple-dose vial and is not reconstituted[5].

▪Sanitize: Swab the vial stopper and the bacteriostatic-water stopper with fresh alcohol pads and let them air-dry.

▪Add diluent slowly: Draw 2.0 mL bacteriostatic water and run it down the inside wall of the vial rather than jetting it onto the powder.

▪Dissolve gently: Swirl until clear; never shake. Setmelanotide is cyclic and comparatively robust, but shaking still foams and shears peptide solutions.

▪Store and label: Refrigerate at 2–8 °C and write the date and the concentration — 5 mg/mL — on the vial, because it is not the 10 mg/mL of the approved product.

Storage Instructions

Research-grade lyophilized vials: store refrigerated or frozen, away from light, until reconstitution. Setmelanotide is a cyclic peptide, which makes it structurally more stable than a comparable linear sequence, but it is handled like any other lyophilized peptide.

After reconstitution, refrigerate at 2–8 °C and use within the bacteriostatic-water window (commonly cited as up to ~28 days) — at the maintenance dose the vial is emptied long before that matters. Discard if the solution becomes cloudy or discolored.

Important Notes

The points below are the ones that most change how setmelanotide should be read — particularly by anyone who encountered it as “the MC4R weight-loss peptide”.

▪It is not a general weight-loss drug, and the evidence is explicit about why: Setmelanotide works by agonizing MC4R, so it helps when the break is upstream of an intact receptor. The Cambridge/Rhythm study that tested this directly found patients with POMC defects upstream of MC4R lost significantly more weight than MC4R-deficient patients or obese controls, and MC4R-knockout mice failed to respond at all[4]. Common obesity is not an upstream-of-MC4R disease, and setmelanotide is not approved for it.

▪The pivotal trials were tiny: The phase 3 programme that won the first approval enrolled 10 patients with POMC deficiency and 11 with LEPR deficiency — single-arm and open-label, because the diseases are vanishingly rare. Eight of ten (80%) POMC patients and five of eleven (45%) LEPR patients reached at least 10% weight loss at about one year[1]. That is a real result and an appropriate design for an ultra-rare disease. It is not the evidence base people assume when they hear “FDA-approved for weight”.

▪The randomized data are more modest than the headline: In the only placebo-controlled phase 3 of the original programme (38 patients), 32.3% of Bardet-Biedl patients aged 12+ reached at least 10% weight loss after 52 weeks — and the results in Alström syndrome were inconclusive[2]. The larger TRANSCEND trial in acquired hypothalamic obesity (142 patients) was the strongest result: −18.4% placebo-adjusted BMI, with −15.8% on drug versus +2.6% on placebo at 52 weeks (p<0.0001)[6].

▪Hyperpigmentation is expected, not a rare event: Setmelanotide is selective for MC4R but not exclusive to it, and MC1R activation darkens skin. Skin hyperpigmentation occurred in all ten POMC patients in the phase 3 trial[1] and in 61% of the Bardet-Biedl/Alström cohort[2]. The label carries a warning covering hyperpigmentation, darkening of pre-existing nevi and development of new melanocytic nevi, with a full skin examination advised before and during treatment[5].

▪The label warnings are specific and worth reading: There is no boxed warning, but IMCIVREE carries warnings for disturbance in sexual arousal (spontaneous penile erections; seek emergency care beyond 4 hours), depression and suicidal ideation, hypersensitivity reactions, the skin/nevi warning above, and — specific to acquired hypothalamic obesity — acute adrenal insufficiency and sodium imbalance in patients with central diabetes insipidus[5]. The last two exist because that population often has other pituitary deficits; they are a clear illustration of why this drug is prescribed and monitored rather than self-run.

▪Every pivotal trial was funded by the manufacturer: The POMC/LEPR, Bardet-Biedl and MC4R studies were all funded by Rhythm Pharmaceuticals, with company employees among the authors[1][2][4]. That is normal for orphan-drug development and the trials were published in peer-reviewed journals with regulatory review behind them — it is noted for completeness, not as an accusation.

How This Works

The leptin-melanocortin pathway is the brain’s core energy-balance circuit. Leptin from fat tissue signals to POMC neurons in the hypothalamus; POMC is cleaved by PCSK1 into melanocortin peptides including α-MSH; α-MSH then activates MC4R on downstream neurons, which suppresses appetite[3]. Break any link — the leptin receptor (LEPR), POMC itself, or the PCSK1 enzyme — and the MC4R never receives its signal. The result is the phenotype these patients live with: extreme early-onset obesity driven by hyperphagia, a hunger that is physiological rather than behavioural.

Setmelanotide’s insight is to bypass the broken upstream link and stimulate MC4R directly. It is significantly more potent at MC4R than α-MSH itself, the endogenous ligand, and can disproportionately rescue signaling by a subset of severely impaired MC4R mutants[4]. This explains both the efficacy and its limits with unusual clarity: the drug substitutes for a missing signal, so it works where the signal is missing and the receptor is intact, and it cannot work where the receptor itself is gone — which is precisely what MC4R-knockout mice showed[4]. The first proof in humans was stark: two POMC-deficient patients had sustained reductions in hunger and lost 51.0 kg and 20.5 kg[3]. The same non-exclusive receptor selectivity that makes it useful also produces the hyperpigmentation, via MC1R on melanocytes.

Lifestyle Factors

The honest lifestyle note for setmelanotide is that it addresses something lifestyle advice cannot reach. In POMC, PCSK1 or LEPR deficiency the hunger is a missing satiety signal, and telling such a patient to eat less describes the symptom rather than the cause. What the trials measured alongside weight was hunger — the most-hunger score fell 27.1% in the POMC trial and 43.7% in the LEPR trial[1] — and that reduction is the mechanism the weight loss follows from.

The converse is the part worth internalising: because the drug replaces a specific missing signal, none of that reasoning transfers to someone whose melanocortin pathway is intact. For common obesity the interventions with real human evidence remain diet, activity, sleep and, where appropriate, the incretin drugs — not an MC4R agonist aimed at a defect that is not there.

Potential Benefits & Side Effects

Unusually for this site, most of the evidence below is from randomized or regulator-reviewed human trials rather than animals. The essential qualifier is the population: these results come from patients with specific diagnosed genetic or hypothalamic conditions, and do not generalize to common obesity.

Reported Effects

▪Weight loss in POMC and LEPR deficiency (human, phase 3): 80% of POMC patients (8/10) and 45% of LEPR patients (5/11) achieved at least 10% weight loss at about one year in single-arm open-label trials[1].

▪Reduced hunger (human, phase 3): Most-hunger scores fell 27.1% (POMC) and 43.7% (LEPR) on therapeutic dosing — the hyperphagia endpoint that matters most to these patients[1].

▪Weight loss in Bardet-Biedl syndrome (human, randomized phase 3): 32.3% of patients aged 12+ reached at least 10% weight loss after 52 weeks; the same trial was inconclusive in Alström syndrome[2].

▪BMI reduction in acquired hypothalamic obesity (human, randomized phase 3): TRANSCEND (142 patients) reported a −18.4% placebo-adjusted BMI reduction at 52 weeks — −15.8% on drug versus +2.6% on placebo (p<0.0001) — supporting the March 2026 approval[6][7].

▪Proof of concept (human, first-in-patient): The two original POMC-deficient patients lost 51.0 kg over 42 weeks and 20.5 kg over 12 weeks, with sustained reduction in hunger[3].

Common Side Effects

▪Skin hyperpigmentation — near-universal: Reported in all ten POMC phase 3 patients[1] and 61% of the Bardet-Biedl/Alström cohort[2]. It typically appears within 2–3 weeks, and the label additionally warns about darkening of existing moles and new melanocytic nevi, advising skin examination before and during treatment[5].

▪Injection-site reactions — also near-universal: Reported in all patients in both the POMC and LEPR trials[1], and in 48% of the Bardet-Biedl/Alström cohort as injection-site erythema[2].

▪Disturbance in sexual arousal: Spontaneous penile erections in males and sexual adverse reactions in females are a labelled warning; an erection lasting more than 4 hours requires emergency care[5]. This is the melanocortin-family effect that PT-141 was developed to exploit deliberately.

▪Depression and suicidal ideation: A labelled warning — centrally acting drugs of this class may cause depression or suicidal ideation, and monitoring is advised[5]. Suicidal ideation appeared among the serious adverse events recorded in the Bardet-Biedl trial, though it was not considered treatment-related[2].

▪Gastrointestinal and hypothalamic-specific risks: Nausea, vomiting, diarrhoea, abdominal pain and headache are common[1][5]. In acquired hypothalamic obesity the label adds warnings for acute adrenal insufficiency and sodium imbalance with central diabetes insipidus — risks that only a clinician managing the underlying pituitary disease can monitor[5].

Injection Technique

General handling practice for a reconstituted research vial. The approved product is prescribed, dispensed as a ready-to-use solution, and administered under medical supervision — which, given the adrenal, sodium and psychiatric warnings on its label, is the point rather than a formality.

Pre-Injection Preparation

▪Confirm your concentration: A 10 mg research vial in 2 mL is 5 mg/mL, not the 10 mg/mL of the approved solution — recompute every dose in milligrams rather than copying a volume.

▪Inspect: The solution should be clear to slightly opalescent and free of particulates; discard if cloudy or discolored.

▪Dose in the morning: The label specifies administration at the beginning of the day[5].

Injection Procedure

▪Swab: Clean the site with an alcohol pad and let it dry fully before injecting.

▪Inject subcutaneously: Pinch the skin and enter the subcutaneous layer at 45–90° — abdomen, thigh or upper arm.

▪Rotate sites: Injection-site reactions occurred in essentially every trial patient[1], so rotating sites is not optional housekeeping here.

Post-Injection Care

▪Dispose properly: Never recap; put the syringe straight into a sharps container.

▪Return to cold storage: Refrigerate the vial at 2–8 °C promptly, away from light.

▪Watch the skin: Hyperpigmentation appears within 2–3 weeks and the label advises monitoring moles for change[5] — document any new or changing lesion.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for Setmelanotide (10 mg Vial).

Why Prime Lab Peptides?

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.

▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.

▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.

▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.

▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

References

View Source ↗

Setmelanotide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.

There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.

On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.

Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.

Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.

No. Setmelanotide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

New protocols & dosing updates

Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.

Written by Dr. Aimen Arij, PharmD

Related Metabolic & Weight protocols